Trophos successfully completes phase 1 study for novel cardioprotective compound, TRO40303
Phase 2 Proof-of-Concept study in acute myocardial infarction planned for second half 2011 with MitoCare EU consortium
28-Feb-2011 -
Trophos SA a clinical stage pharmaceutical company developing innovative therapeutics from discovery to clinical validation for indications with under-served needs in neurology and cardiology, announces today the successful completion of its phase 1 dose escalation study of TRO40303, a novel ...
cardiovascular diseases
mitochondria
myocardial infarction